Liver cancer diagnosis remains a challenge, since imaging techniques, such as computed tomography and dynamic contrast enhanced magnetic resonance, as well as dosage of serum biomarkers, such as α-fetoprotein (AFP), carbohydrate antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA), have low sensitivity and specificity for the diagnosis of small neoplastic nodules [7]. This evidence concerns the gene CEACAM5 and liver cancer.